While the activation of Nrf2 leads to cytoprotection and a significant reduction in cisplatin-induced kidney injury [113,114], it can also confer resistance in cancer cells, potentially compromising the effectiveness of chemotherapy [137,138]. This evidence concerns the gene NFE2L2 and cancer.